Priority Lists
Protocol Posting of
Activations
Closures
Phase II Trial of Concurrent Carboplatin/VP-16 and Radiation Followed by Paclitaxel (Taxol®) For Poor-Risk Stage III Non-Small Cell Lung Cancer
Study Coordinator(s) | Derick H.M. Lau, M.D.,Ph.D., David R. Gandara, M.D., Laurie E. Gaspar, M.D. |
Participants | Members, NCORP |
Closure Date | 2000-06-01 |
Amendments, Revisions, Memoranda
Revision #7
Phase III Trial of High Dose Interferon Alpha-2b versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma
Study Coordinator(s) | Lawrence E. Flaherty, M.D., John A. Thompson, M.D., Ralph J. Tuthill, M.D., John Vetto, M.D., Vernon K. Sondak, M.D., Jeffrey A. Sosman, M.D. |
Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists, ECOG, COG, US INSTITUTIONS ONLY |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required